RxDoctor Payments Data

Amy Saleh, MD

Otolaryngology · Rochester, NYNPI 1912197740

Payments from drug & device makers

$1,174in general payments, 2019–2025

Across 30 payments — averaging $39.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$218
  • Aerin Medical Inc.$158
  • ARS Pharmaceuticals Operations, Inc.$125
  • Medtronic$103
  • GSK$98
  • Regeneron Healthcare Solutions, Inc.$95
  • plus $376 from 11 others

What the payments were for

  • Food & beverage$1,174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,174 in reported general payments places this provider in the 50th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$82,637
Medicare patients
221
Services billed
2,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate233$3,008
Azelastine Hcl107$2,982
Mometasone Furoate30$2,652
Tobramycin-DexamethasoneTobramycin/Dexamethasone28$2,297
Azelastine-FluticasoneAzelastine/Fluticasone22$2,200
SynthroidLevothyroxine Sodium20$1,560
Levocetirizine Dihydrochloride105$1,308
Ipratropium Bromide61$1,301
Ofloxacin27$1,272
Levothyroxine Sodium51$734
Montelukast Sodium57$405
Clotrimazole11$382
Methylprednisolone31$278
Cefdinir14$235
Celecoxib16$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$73451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →